These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 1485272)

  • 21. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
    Fuks JZ; Aisner J; Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1982 Sep; 66(9):1773-4. PubMed ID: 7116354
    [No Abstract]   [Full Text] [Related]  

  • 23. Advanced adenocarcinoma of the kidney: therapy with lomustine, vinblastine, hydroxyurea, and medroxyprogesterone acetate and regression analysis of factors relating to survival.
    Brubaker LH; Troner MB; Birch R
    Cancer Treat Rep; 1983; 67(7-8):741-2. PubMed ID: 6223695
    [No Abstract]   [Full Text] [Related]  

  • 24. Tamoxifen: an overview of recent studies in the field of oncology.
    Patterson JS; Battersby LA
    Cancer Treat Rep; 1980; 64(6-7):775-8. PubMed ID: 7000349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Estrogen and progesterone receptors in endometrial carcinoma during high-dose progestogen (Depo-Provera) therapy].
    Thurzó L; Sas M; Falkay G
    Orv Hetil; 1986 Oct; 127(43):2613-6. PubMed ID: 2947029
    [No Abstract]   [Full Text] [Related]  

  • 26. [Estrogen plus gestagen especially risky. Breast cancer risk doubled].
    MMW Fortschr Med; 2003 Nov; 145(46):8. PubMed ID: 14699823
    [No Abstract]   [Full Text] [Related]  

  • 27. [Plasma concentrations of non-esterified fatty acids and lipids in high-dose medroxyprogesterone therapy of metastatic breast cancer].
    Hofmann M; Holzer A; Brockerhoff P; Rathgen GH
    Zentralbl Gynakol; 1993; 115(11):495-9. PubMed ID: 8296495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [the oral use of a progestational hormone (Provera 100) as an adjuvant in therapy of adenocarcinoma of the kidney. Preliminary report].
    Liberti M; Di Silverio F; Concolino G; Tenaglia R; Marocchi A
    Minerva Urol; 1980; 32(3):175-8. PubMed ID: 7432332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Massive-dose progestational therapy in oncology (medroxyprogesterone). Preliminary results.
    Pannuti F; Martoni A; Pollutri E; Camera P; Losinno F; Giusti H
    Panminerva Med; 1976; 18(3-4):129-36. PubMed ID: 176620
    [No Abstract]   [Full Text] [Related]  

  • 30. Medroxyprogesterone acetate induced Cushing's syndrome.
    Shotliff K; Nussey SS
    Br J Clin Pharmacol; 1997 Sep; 44(3):304. PubMed ID: 9296330
    [No Abstract]   [Full Text] [Related]  

  • 31. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
    Feng YJ; Zhang XY
    Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Drug treatment of uterine fibromas].
    Boubli L
    J Gynecol Obstet Biol Reprod (Paris); 1999 Nov; 28(7):729-31. PubMed ID: 10624625
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report.
    Hines BJ; Porges RF; Mittal K; Muggia FM; Curtin JP
    Gynecol Oncol; 2002 Apr; 85(1):192-5. PubMed ID: 11925144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Breast cancer and hormone therapy].
    Izuo M
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2830-6. PubMed ID: 2959203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case of breast cancer with metastasis of multiple organs showing marked efficacy of medroxyprogesterone acetate (MPA)].
    Shimada K; Karaki Y; Ansai Y; Hino K; Yamashita Y; Fujimaki M
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):623-6. PubMed ID: 8678522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medroxyprogesterone acetate and lipid metabolic changes.
    Teichmann AT; Wander HE; Cremer P; Wieland H; Kuhn W; Nagel GA; Seidel D
    Arzneimittelforschung; 1987 May; 37(5):573-7. PubMed ID: 2956958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mammary gland carcinoma treated by large-dose medroxyprogesterone acetate of which pulmonary metastases disappeared and a selection of hormone, chemoimmunological treatment].
    Matsumoto S; Kutsuna T; Tann M; Mizuno Y; Shinohara M; Kimura T; Banno T; Yoshizaki S
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2457-9. PubMed ID: 2526619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate.
    Kline RC; Freedman RS; Jones LA; Atkinson EN
    Cancer Treat Rep; 1987 Mar; 71(3):327-8. PubMed ID: 2949831
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.